Firebrick Pharma Ltd
ASX:FRE
Firebrick Pharma Ltd
Research & Development
Firebrick Pharma Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
Research & Development
-AU$735.2k
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$30m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Research & Development
-AU$144k
|
CAGR 3-Years
76%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
See Also
What is Firebrick Pharma Ltd's Research & Development?
Research & Development
-735.2k
AUD
Based on the financial report for Jun 30, 2025, Firebrick Pharma Ltd's Research & Development amounts to -735.2k AUD.
What is Firebrick Pharma Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
15%
Over the last year, the Research & Development growth was 61%. The average annual Research & Development growth rates for Firebrick Pharma Ltd have been 31% over the past three years , 15% over the past five years .
